Researchers at the University of Michigan wrote “Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes” for the January 2017 issue of  The AAPS Journal. In the article, the scientists used Spectra/Por® Float-A-Lyzers® to develop a new drug release assay for doxorubicin liposomes.

Abstract: Doxil® is a complex parenteral doxorubicin (DOX) liposome formulation approved by the FDA. For generic doxorubicin liposomes, analyzing the release profile of DOX is important for quality control and comparability studies. However, there is no robust standard drug release assay available for doxorubicin liposomes. In this study, we describe a USP-4 apparatus assay capable of discriminating DOX liposomal formulations based on release profile. Click here to read the article.

 

The Spectra/Por® Float-A-Lyzer® G2, the next generation in Ready-to-Use laboratory dialysis devices, featuring proprietary Ultra-Pure Biotech Cellulose Ester (CE) Membrane.

doi: 10.1208/s12248-016-9958-2